South SudanTuberculosis profile
Population  2014 12 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 3.4 (2.4–4.7) 29 (20–39)
Mortality (HIV+TB only) 0 (–) 0 (–)
Prevalence  (includes HIV+TB) 38 (17–68) 319 (139–572)
Incidence  (includes HIV+TB) 17 (14–21) 146 (121–173)
Incidence (HIV+TB only) 2.9 (2.3–3.6) 25 (20–30)
         
Case detection, all forms (%) 48 (40–58)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 2.2 (0.3–4.1) 11 (6.2–16)
MDR-TB cases among notified pulmonary
TB cases
140 (19–260) 85 (48–120)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 3 565   259
Pulmonary, clinically diagnosed 2 887    
Extrapulmonary 1 624    
       
Total new and relapse 8 335    
Previously treated, excluding relapses 521    
Total cases notified 8 856    
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 0 (0%) 56 (7%) 56
Laboratory-confirmed RR-/MDR-TB cases     6
Patients started on MDR-TB treatment ***     0
TB/HIV 2014 Number (%)
TB patients with known HIV status 5 892 (67)
HIV-positive TB patients 752 (13)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 713 (95)
HIV-positive TB patients on antiretroviral therapy (ART) 463 (62)
HIV-positive people screened for TB 17 885  
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (72) 7 240
Previously treated cases, excluding relapse, registered in 2013 (58) 559
HIV-positive TB cases, all types, registered in 2013 (62) 701
RR-/MDR-TB cases started on second-line treatment in 2012    
XDR-TB cases started on second-line treatment in 2012    
Laboratories 2014  
Smear (per 100 000 population) 0.7
Culture (per 5 million population) 0
Drug susceptibility testing (per 5 million population) 0
Sites performing Xpert MTB/RIF 1
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2015  
National TB programme budget (US$ millions) 9.6
% Funded domestically 7%
% Funded internationally 55%
% Unfunded 38%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-10-01 Data: www.who.int/tb/data